MIRA Pharmaceuticals Says 7-Day Repeated-Dose Dog Study Of Obesity Candidate SKNY-1 Showed Dose-Dependent Exposure, Supporting Advancement Toward GLP Toxicology, IND-Enabling Work
Share
Why It Matters
MIRA tested a medicine for weight loss on dogs to understand how it works in the body—and the results look like they're on the right path. This means the company can move forward with more testing steps to eventually try the drug on people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.